Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Efficacy And Safety Of Ipilimumab Monotherapy In Patients With Pretreated Advanced Melanoma: A Multicenter Single-arm Phase II Study.
S. O’Day, M. Maio, V. Chiarion-Sileni, T. Gajewski, H. Pehamberger, I. Bondarenko, P. Queirolo, L. Lundgren, S. Mikhailov, L. Roman, C. Verschraegen, R. Humphrey, R. Ibrahim, V. de Pril, A. Hoos, J. Wolchok
Published 2010 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
BACKGROUND This phase II study evaluated the safety and activity of ipilimumab, a fully human mAb that blocks cytotoxic T-lymphocyte antigen-4, in patients with advanced melanoma. PATIENTS AND METHODS Patients with previously treated, unresectable stage III/stage IV melanoma received 10 mg/kg ipilimumab every 3 weeks for four cycles (induction) followed by maintenance therapy every 3 months. The primary end point was best overall response rate (BORR) using modified World Health Organization (WHO) criteria. We also carried out an exploratory analysis of proposed immune-related response criteria (irRC). RESULTS BORR was 5.8% with a disease control rate (DCR) of 27% (N = 155). One- and 2-year survival rates (95% confidence interval) were 47.2% (39.5% to 55.1%) and 32.8% (25.4% to 40.5%), respectively, with a median overall survival of 10.2 months (7.6-16.3). Of 43 patients with disease progression by modified WHO criteria, 12 had disease control by irRC (8% of all treated patients), resulting in a total DCR of 35%. Adverse events (AEs) were largely immune related, occurring mainly in the skin and gastrointestinal tract, with 19% grade 3 and 3.2% grade 4. Immune-related AEs were manageable and generally reversible with corticosteroids. CONCLUSION Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population.
This paper references
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
A. Maker (2005)
Immunostimulatory monoclonal antibodies for cancer therapy
I. Melero (2007)
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma
W. Kruit (2005)
Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade
Stephanie G Downey (2007)
Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
O. Hamid (2009)
Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events
JS Weber (2007)
Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine
Evan M. Hersh (2008)
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
G. Ku (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
J. Wolchok (2009)
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer.
E. Kwon (1997)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
A companion study for patients enrolled in prior/parent ipilimumab studies http://clinicaltrials.gov/show
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
S. O’Day (2007)
Current systemic therapy for metastatic melanoma
S. Agarwala (2009)
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
A. Hauschild (2009)
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
L. Fong (2008)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
K. Peggs (2006)
A Confidence Interval for the Median Survival Time
R. Brookmeyer (1982)
THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
C. J. Clopper (1934)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
J. Weber (2009)
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
J. Weber (2007)
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
F. S. Hodi (2003)
Phase I/II study of ipilimumab for patients with metastatic melanoma.
J. Weber (2008)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide
D. Berman (2008)
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
A. Maker (2006)
Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an antiCTLA4 therapy
K Chin (2008)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
P. Attia (2005)
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
N. van Baren (2005)
Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma
Agop Y. Bedikian (2008)
This paper is referenced by
Behandlung und Nebenwirkungsmanagement des metastasierten Melanoms mit CTLA‐4‐Antikörpern
K. Kähler (2011)
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
D. Wang (2017)
Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.
J. Weber (2013)
Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors
E. Minutilli (2012)
Current and Emerging Therapies in Pancreatic Cancer
T. Bekaii-Saab (2018)
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
T. Eigentler (2011)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
M. Nishino (2013)
Challenges and approaches for the development of safer immunomodulatory biologics
Jean G. Sathish (2013)
The safety of anti PD-1 therapeutics for the treatment of melanoma
E. Ramelyte (2017)
Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
A. Faje (2014)
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.
J. Wolchok (2013)
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
G. Tosti (2013)
Quoi de neuf en cancérologie cutanée
Gaëlle Quéreux (2013)
Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma
Weill Cornell (2015)
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Yinghao Zhao (2018)
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
E. Simeone (2012)
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
Shintaro Iwama (2014)
Immune checkpoint inhibitors: a new frontier in bladder cancer
M. Kates (2015)
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
S. Ferrari (2019)
Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma.
Shiya Zheng (2018)
Novel insights/translational implication from the emerging biology of melanoma.
A. Ribas (2014)
Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications
M. Liu (2016)
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
P. Ascierto (2011)
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
J. Luke (2013)
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
B. Chmielowski (2013)
Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial
J. Weber (2011)
Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
G. Piérard (2012)
Immune‐related adverse reactions in the hepatobiliary system: second‐generation check‐point inhibitors highlight diverse histological changes
Y. Zen (2019)
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
S. Cuzzubbo (2017)
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.
Emanuelle M. Rizk (2019)
Endocrinological side-effects of immune checkpoint inhibitors
F. Torino (2016)
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
Seongseok Yun (2016)See more